CAMELIA

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

CAMELIA [NCT02019264]

Description: This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with CV disease and/or multiple CV risk factors.

Drug: APD356-Lorcaserin hydrochloride; Drug: Placebo

Primary Investigator: Kereiakes

Drug/Device Information
Effect of BELVIQ on cardiovascular events and conversion to Type 2 DM in obese/overweight subjects with cardiovascular disease or cardiovascular risk factors
APD356/BELVIQ (lorcaserin hydrochloride) is a selective serotonin 2c receptor agonist
Randomized 1:1 to lorcaserin HCl 10 mg BID or placebo
Eisai Inc.